MedTrace Logo

Validation Of The Flemish Montreal Cognitive Assessment (MoCA) For Persons With Hearing Impairment

NCT06400173 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2024-05-06

No results posted yet for this study

Summary

The Montreal Cognitive Assessment (MoCA) is a screening test for detecting cognitive impairment that assesses several cognitive domains (attention and concentration, arithmetic and orientation, memory, etc.). The instructions as well as some test items of the MoCA are presented auditory (spoken). Consequently, performance on the MoCA may be co-dependent on hearing. Therefore, to rule out the possible negative influence of hearing loss on performance on the MoCA, a MoCA for individuals with hearing loss was recently developed. More specifically, the original MoCA was modified by providing the instructions audiovisually (spoken with visual support) as well as by replacing hearing-dependent items. Since replacing items may affect sensitivity and specificity, the MoCA for persons with hearing loss should be revalidated.

Conditions

Interventions

BEHAVIORAL

Cognitive screening

The Dutch Montreal Cognitive Assessment for persons with hearing loss (MoCA-HI) is a modified version of the original MoCA test specifically designed for individuals with hearing loss. It includes adaptations such as visual aids to accommodate for hearing loss, ensuring fair assessment of cognitive abilities in this population.

BEHAVIORAL

Audiological Assessment

Four audiological tests are included in the audiological assessment 1. Tympanometry to assss the middle ear status 2. Pure-tone audiometry with headphone to evaluate the hearing thresholds 3. Speech audiometry in free field to assess the ability to understand spoken words in the presence of background noise 4. The hAVICOP questionnaire to assess the hearing-related quality of life

Sponsors & Collaborators

  • University Hospital, Ghent

    collaborator OTHER

  • University Ghent

    lead OTHER

Principal Investigators

  • Tim Van Langenhove, MD, PhD · University Hospital, Ghent

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06400173 on ClinicalTrials.gov